Abstract
Type II topoisomerases (TOPO2) are ubiquitously expressed enzymes that overcome topological problems in genomic DNA, which can result from DNA replication, transcription and repair. The class of compounds targeting TOPO2 includes some of the most active chemotherapy agents currently available for the treatment of patients with different cancer types. Therefore, understanding of the molecular mechanisms underlying resistance to these drugs is of pivotal importance to improve their efficacy and ultimately increase the life expectancy of cancer patients. The first aim of this review is to summarize the molecular biology of TOPO2 inhibitors, which is the key to understand cancer resistance to them; the second part of this work is dedicated to overview and discuss the available evidence on the mechanisms of resistance to these drugs, with special attention to the strategies that might be useful to circumvent this phenomenon on the clinical ground.
Keywords: Cancer, chemoresistance, chemotherapy, topoisomerase, DNA repair, Type II topoisomerases, ubiquitously expressed enzymes, genomic DNA, drugs, biology of TOPO2 inhibitors
Current Medicinal Chemistry
Title:Cancer Resistance to Type II Topoisomerase Inhibitors
Volume: 19 Issue: 23
Author(s): P. Pilati, D. Nitti and S. Mocellin
Affiliation:
Keywords: Cancer, chemoresistance, chemotherapy, topoisomerase, DNA repair, Type II topoisomerases, ubiquitously expressed enzymes, genomic DNA, drugs, biology of TOPO2 inhibitors
Abstract: Type II topoisomerases (TOPO2) are ubiquitously expressed enzymes that overcome topological problems in genomic DNA, which can result from DNA replication, transcription and repair. The class of compounds targeting TOPO2 includes some of the most active chemotherapy agents currently available for the treatment of patients with different cancer types. Therefore, understanding of the molecular mechanisms underlying resistance to these drugs is of pivotal importance to improve their efficacy and ultimately increase the life expectancy of cancer patients. The first aim of this review is to summarize the molecular biology of TOPO2 inhibitors, which is the key to understand cancer resistance to them; the second part of this work is dedicated to overview and discuss the available evidence on the mechanisms of resistance to these drugs, with special attention to the strategies that might be useful to circumvent this phenomenon on the clinical ground.
Export Options
About this article
Cite this article as:
Pilati P., Nitti D. and Mocellin S., Cancer Resistance to Type II Topoisomerase Inhibitors, Current Medicinal Chemistry 2012; 19 (23) . https://dx.doi.org/10.2174/092986712802002473
DOI https://dx.doi.org/10.2174/092986712802002473 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Heat Shock Protein 90 Inhibitors as Therapeutic Agents
Recent Patents on Anti-Cancer Drug Discovery Nanotechnology for Alzheimer Disease
Current Alzheimer Research Dose-Intensive Chemotherapy with Stem Cell Support as a Treatment Strategy for Bone and Soft-Tissue Sarcomas
Current Stem Cell Research & Therapy Therapeutic Benefit and Biological Importance of Ginkgetin in the Medicine: Medicinal Importance, Pharmacological Activities and Analytical Aspects
Current Bioactive Compounds Use of Anticancer Platinum Compounds in Combination Therapies and Challenges in Drug Delivery
Current Medicinal Chemistry Antineoplastic Action of Growth Hormone-Releasing Hormone (GHRH) Antagonists
Recent Patents on Anti-Cancer Drug Discovery Peptidic Tumor Targeting Agents: The Road from Phage Display Peptide Selections to Clinical Applications
Current Pharmaceutical Design The Urokinase-type Plasminogen Activator and the Generation of Inhibitors of Urokinase Activity and Signaling
Current Pharmaceutical Design Nanotechnology in the Management of Bone Diseases and as Regenerative Medicine
Current Nanoscience EDITORIAL [Hot Topic-I: Molecular and Pharmacological Aspects of Existing and Experimental Bone Anabolic Therapies (Guest Editor: Naibedya Chattopadhyay)]
Current Molecular Pharmacology Induction of Thyroid Neoplasm Following Plant Medicine Marine Algae (Sargassum): A Rare Case and Review of the Literature
Current Pharmaceutical Biotechnology Targeting RhoA/Rho Kinase and p21-Activated Kinase Signaling to Prevent Cancer Development and Progression
Recent Patents on Anti-Cancer Drug Discovery Can PPARγ Ligands Be Used in Cancer Therapy?
Current Medicinal Chemistry - Anti-Cancer Agents Modified Polysaccharides as Carriers for Biomolecules
Pharmaceutical Nanotechnology Immunomodulation and Anti-inflammatory Roles of Polyphenols as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry DNA Damage-inducing Compounds: Unraveling their Pleiotropic Effects Using High Throughput Sequencing
Current Medicinal Chemistry Anticancer Potential of Dietary Natural Products: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry SUMOylation Modulates CFTR Biogenesis: Is the Pathway Druggable?
Current Drug Targets Effect of Intestinal Flora Clearance on Liver Proteomics in Mice
Current Proteomics Intestinal Dysbiosis, Gut Hyperpermeability and Bacterial Translocation: Missing Links Between Depression, Obesity and Type 2 Diabetes
Current Pharmaceutical Design